Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1021. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance

Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance Cost effectiveness of ramipril in patients with non (...) -diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance Schadlich P K, Brecht J G, Brunetti M, Pagano E, Rangoonwala B, Huppertz E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

NHS Economic Evaluation Database.2001

1022. Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs

Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs Richter A, Gondek K, Ostrowski C, Dombeck M, Lamb S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of telmisartan (40 - 120 mg daily), an angiotensin-II inhibitor used for the treatment of mild-to-moderate uncomplicated hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised hypothetical patients

NHS Economic Evaluation Database.2001

1023. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic

Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic Okamoto M P, Nakahiro R K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Hypertension care, as provided by either a pharmacist-managed hypertension clinic or physician-managed general medical clinics, was examined. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with mild-to-moderate essential hypertension. Patients were included in the study if they were at least 18 years old, had been members of the managed care

NHS Economic Evaluation Database.2001

1024. Costs-effectiveness of the urban health center in Nakhon Ratchasima: a case study on diabetes and hypertension.

Costs-effectiveness of the urban health center in Nakhon Ratchasima: a case study on diabetes and hypertension. Costs-effectiveness of the urban health center in Nakhon Ratchasima: a case study on diabetes and hypertension. Costs-effectiveness of the urban health center in Nakhon Ratchasima: a case study on diabetes and hypertension. Pannarunothai S, Kongpan M, Mangklasiri R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) unselected patients suffering from diabetes and hypertension. Setting The setting was primary care. The economic study was carried out in the province of Nakhon Ratchasima in Thailand. Dates to which data relate The effectiveness and resource use data were gathered between 1994 and 1996 for groups 1 and 2, and in 1997 for group 3. No price year was reported. Source of effectiveness data The effectiveness evidence was derived from a single study. Link between effectiveness and cost data The costing

NHS Economic Evaluation Database.2001

1025. Omapatrilat for the management of heart failure and hypertension

Omapatrilat for the management of heart failure and hypertension Omapatrilat for the management of heart failure and hypertension Omapatrilat for the management of heart failure and hypertension Husereau D R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Husereau D R. Omapatrilat for the management of heart failure and hypertension (...) . Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on the use of omapatrilat for the management of heart failure and hypertension. Authors' conclusions - Omapatrilat, first in a new class of cardiovascular drugs called vasopeptidase inhibitors, is under evaluation for the management of hypertension and heart failure. - Several small

Health Technology Assessment (HTA) Database.2001

1026. Inhaled nitric oxide in neonates with persistent pulmonary hypertension.

Inhaled nitric oxide in neonates with persistent pulmonary hypertension. 11197402 2001 01 22 2001 03 29 2015 06 16 0140-6736 357 9250 2001 Jan 13 Lancet (London, England) Lancet Inhaled nitric oxide in neonates with persistent pulmonary hypertension. 118-20 To investigate the oxygenation and haemodynamic dose response to inhaled nitric oxide in neonates with persistent pulmonary hypertension (PPHN), we gave seven neonates nitric oxide and measured directly pulmonary arterial pressure. Inhaled (...) Support, U.S. Gov't, P.H.S. England Lancet 2985213R 0140-6736 0 Vasodilator Agents 31C4KY9ESH Nitric Oxide AIM IM Administration, Inhalation Humans Hypertension, Pulmonary drug therapy Infant, Newborn Nitric Oxide administration & dosage Vasodilator Agents administration & dosage 2001 2 24 12 0 2001 4 3 10 1 2001 2 24 12 0 ppublish 11197402 S0140-6736(00)03548-0 10.1016/S0140-6736(00)03548-0

Lancet2001

1027. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial.

Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. 11520524 2001 08 24 2001 09 20 2015 06 16 0140-6736 358 9281 2001 Aug 18 Lancet (London, England) Lancet Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. 539-44 Is cancer related to hypertension and blood (...) pressure? Do antihypertensive drugs promote cancer? Do antihypertensive drugs protect against cancer? We previously analysed the frequency of cardiovascular mortality and morbidity in elderly people who participated in the Swedish Trial in Old Patients with Hypertension 2 (STOP-Hypertension-2). We have also looked at the frequency of cancer in these patients. We randomly assigned 6614 elderly patients with hypertension (mean age 76 years, median time of follow-up 5.3 years) to one of three treatment

Lancet2001

1028. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. 11597664 2001 10 12 2001 10 25 2015 06 16 0140-6736 358 9288 2001 Oct 06 Lancet (London, England) Lancet Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. 1119-23 Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a cause of pulmonary (...) hypertension. We describe the efficacy and safety of bosentan, a dual endothelin-receptor antagonist that can be taken orally, in patients with severe pulmonary hypertension. In this double-blind, placebo-controlled study, 32 patients with pulmonary hypertension (primary or associated with scleroderma) were randomly assigned to bosentan (62.5mg taken twice daily for 4 weeks then 125 mg twice daily) or placebo for a minimum of 12 weeks. The primary endpoint was change in exercise capacity. Secondary

Lancet2001

1029. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. 11386927 2001 06 01 2001 06 28 2016 10 17 0098-7484 285 21 2001 Jun 06 JAMA JAMA Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. 2719-28 Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown (...) , especially among African Americans. To compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine), and a beta-blocker (metoprolol) on hypertensive renal disease progression. Interim analysis of a randomized, double-blind, 3 x 2 factorial trial conducted in 1094 African Americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m(2)) enrolled between February 1995

JAMA2001

1030. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. 11136953 2000 12 20 2001 01 04 2007 11 14 0028-4793 344 1 2001 Jan 04 The New England journal of medicine N. Engl. J. Med. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. 3-10 The effect of dietary composition on blood (...) pressure is a subject of public health importance. We studied the effect of different levels of dietary sodium, in conjunction with the Dietary Approaches to Stop Hypertension (DASH) diet, which is rich in vegetables, fruits, and low-fat dairy products, in persons with and in those without hypertension. A total of 412 participants were randomly assigned to eat either a control diet typical of intake in the United States or the DASH diet. Within the assigned diet, participants ate foods with high, intermediate

NEJM2001

1031. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. BACKGROUND: Mild-moderate hypertension during pregnancy is common. Antihypertensive drugs are often used in the belief that lowering blood pressure will prevent progression to more severe disease, and thereby improve outcome. OBJECTIVES: To assess the effects of antihypertensive drug treatments for women with mild to moderate hypertension during pregnancy. SEARCH STRATEGY: Relevant trials were identified (...) in the register of trials maintained by the Cochrane Pregnancy and Childbirth Group. In addition, the Cochrane Controlled Trial Register, MEDLINE, and EMBASE were searched. Date of last search: October 2000. SELECTION CRITERIA: All randomised trials evaluating any antihypertensive drug treatment for mild to moderate hypertension during pregnancy, defined whenever possible as systolic blood pressure 140-169 mmHg and diastolic blood pressure 90-109 mmHg. Comparisons were of one or more antihypertensive drug(s

Cochrane2001

1032. Management of chronic hypertension during pregnancy

Management of chronic hypertension during pregnancy Management of chronic hypertension during pregnancy Management of chronic hypertension during pregnancy Mulrow C D, Chiquette E, Ferrer R L, Sibai B M, Stevens K R, Harris M, Montgomery K A, Stamm K Authors' objectives To assess the effectiveness and adverse events of pharmacological and non-pharmacological antihypertensive interventions in pregnancy. Searching Sixteen electronic databases (including MEDLINE, EMBASE, CINAHL and HealthSTAR (...) with a placebo, usual care or another agent. Participants included in the review The inclusion criteria for the participants specified women of childbearing age or pregnant with 'mild to moderate' chronic hypertension. For the assessment of harm, non-gravid participants were included. Outcomes assessed in the review The inclusion criteria for primary outcomes were perinatal mortality, growth restriction, pre-term birth, abruption and superimposed pre- eclampsia. The secondary outcomes were stated as Apgar

DARE.2000

1033. Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-analysis

Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-analysis Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-analysis Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-analysis Oliveira C A, Troster E J, Pereira C R Authors' objectives To evaluate the use of inhaled nitric oxide (NO) in the management of persistent pulmonary hypertension (PPHN) of (...) the newborn. Searching MEDLINE, Current Contents and LILACS were searched from January 1990 to March 1998 by cross-referencing the following MeSH terms: 'nitric oxide and infant'; 'nitric oxide and newborn'; 'nitric oxide and pulmonary hypertension'; 'pulmonary hypertension and infant'; 'pulmonary hypertension and newborn'. The references lists of the retrieved articles and other reviews in the area were also searched. Only studies published in English, French, Spanish, and Portuguese were selected. Study

DARE.2000

1034. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials

Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials Magee L A, Elran E, Bull S B, Logan A, Koren B Authors' objectives To examine the benefits and risks of beta-blockers for pregnancy hypertension. Searching The following (...) potential sources were searched for English or French language publications: MEDLINE, from 1966 to December 1997, using the keywords 'adrenergic beta-antagonists', 'maternal mortality', 'pregnancy', 'pregnancy complications', 'perinatology', 'neonatology', 'infant newborn diseases', 'infant' and 'infant mortality'; Excerpta Medica, from 1989 to 1992, to identify papers from Clinical and Experimental Hypertension which was handsearched from 1992 to 1997; Science Citation Index, from 1990 to 1994

DARE.2000

1035. Angiotensin II antagonists for hypertension: are there differences in efficacy

Angiotensin II antagonists for hypertension: are there differences in efficacy Angiotensin II antagonists for hypertension: are there differences in efficacy Angiotensin II antagonists for hypertension: are there differences in efficacy Conlin P R, Spence J D, Williams B, Ribeiro A B, Saito I, Benedict C, Bunt A M Authors' objectives To compare the antihypertensive efficacy of available drugs in the new angiotensin-II-antagonist (AIIA) class. Searching MEDLINE and Current Contents were searched (...) mg); candesartan (8 mg, 8 to 16 mg); losartan (50 mg) plus HCTZ (12.5 mg); valsartan (80 mg) plus HCTZ (12.5 mg); and candesartan (8 mg) plus HCTZ (12.5 mg). Participants included in the review Patients with mild-to-moderate hypertension (diastolic blood-pressure 95 to 115 mm Hg) with no concomitant diseases. Outcomes assessed in the review Mean blood-pressure reduction (clinical measurement of blood-pressure using sphygmomanometer and cuff). Studies using only ambulatory blood-pressure

DARE.2000

1036. Management of mild chronic hypertension during pregnancy: a review

Management of mild chronic hypertension during pregnancy: a review Management of mild chronic hypertension during pregnancy: a review Management of mild chronic hypertension during pregnancy: a review Ferrer R L, Sibai B M, Mulrow C D, Chiquette E, Stevens K R, Cornell J Authors' objectives To conduct a systematic review of evidence relating to the management of mild chronic hypertension during pregnancy. This included the associated risks, benefits and harms of treatment with antihypertensive (...) , pindolol, ketanserin, methyldopa and nifedipine). No trials of non-pharmacologic interventions or foetal monitoring techniques met the review criteria. Participants included in the review Pregnant females with mild-to-moderate chronic hypertension or with chronic hypertension were eligible. Mild-to-moderate chronic hypertension was defined as a blood-pressure (BP) of less than 170/110 mmHg, diagnosed either before pregnancy or before 20 weeks' gestation. Chronic hypertension was defined as known

DARE.2000

1037. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis

Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis von Dadelszen P, Ornstein M P, Bull S B, Logan A G, Koren G, Magee L A Authors' objectives To investigate the relationship between foetoplacental growth and the use of oral antihypertensive (...) medication to treat mild-to-moderate pregnancy hypertension. Searching MEDLINE was searched for trials published between 1966 to 1997 using the following keywords: 'antihypertensive agents', 'bedrest', 'hospitalisation', 'plasma volume expansion', 'plasma substitutes', 'maternal mortality', 'pregnancy', 'pregnancy complications', 'perinatology', 'neonatology', 'infant newborn diseases', 'infant' and 'infant mortality'. Excerpta Medica (from 1989 to 1992) was examined to identify articles in Clinical

DARE.2000

1038. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients

Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients Elliott W J, Weir D R, Black H R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The lower treatment goal, as defined by the Sixth Report of the Joint National Committee on Prevention, Detection, Eradication, and Treatment of High Blood Pressure (JNC VI): to lower blood pressure (BP) in diabetic patents to less than 130/85 mmHg. Type of intervention Treatment and secondary prevention. Economic study type Cost-effectiveness analysis. Study population

NHS Economic Evaluation Database.2000

1039. A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension

A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension Whitcomb C, Enzmann G, Pershadsingh H A, Johnson R, Ciuryla V, Reisin E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two long-acting dihydropyridine calcium antagonists, amlodipine and nisoldipine extended-release, for the treatment of mild to moderate hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised adult patients with Stage I

NHS Economic Evaluation Database.2000

1040. Management of chronic hypertension during pregnancy

Management of chronic hypertension during pregnancy Management of chronic hypertension during pregnancy Management of chronic hypertension during pregnancy Agency for Healthcare Research and Quality (AHRQ) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Agency for Healthcare Research and Quality (AHRQ). Management of chronic hypertension (...) during pregnancy. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 14. 2000 Authors' objectives The purpose of this report is to help clinicians make informed choices about therapeutic interventions for pregnant women with chronic hypertension and to aid organizations developing guidelines for the treatment of this condition. The report evaluates evidence regarding risks of chronic hypertension, benefits and adverse effects of pharmacotherapy

Health Technology Assessment (HTA) Database.2000